Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
Portfolio Pulse from
Akeso, Inc. announced that its bispecific antibody drugs, cadonilimab and ivonescimab, have been included in China's National Reimbursement Drug List, potentially boosting their market presence and sales.
November 28, 2024 | 4:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akeso's inclusion of cadonilimab and ivonescimab in China's National Reimbursement Drug List could enhance the company's market presence and sales in China.
The inclusion of Akeso's drugs in the National Reimbursement Drug List is a significant regulatory milestone that can lead to increased sales and market penetration in China, positively impacting the company's financial performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80